{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-fungal+agent", "query": { "intervention": "Anti-fungal agent" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 19, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Anti-fungal+agent&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-27T06:24:52.002Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04847050", "title": "A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumor Malignancy", "Hematologic Malignancy", "Leukemia", "Lymphoma", "Multiple Myeloma" ], "interventions": [ { "name": "Messenger ribonucleic acid (mRNA)-1273 Vaccine", "type": "BIOLOGICAL" }, { "name": "Messenger ribonucleic acid (mRNA)-1273 Vaccine Booster", "type": "BIOLOGICAL" }, { "name": "ECG", "type": "DIAGNOSTIC_TEST" }, { "name": "Antibiotics", "type": "OTHER" }, { "name": "Anti-viral agents", "type": "OTHER" }, { "name": "Anti-fungal agent", "type": "OTHER" }, { "name": "Anti-emetics", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DIAGNOSTIC_TEST", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 19, "start_date": "2021-04-28", "completion_date": "2023-05-25", "has_results": true, "last_update_posted_date": "2024-08-27", "last_synced_at": "2026-09-27T06:24:52.002Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04847050" }, { "nct_id": "NCT04368559", "title": "Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Candidemia", "Mycoses", "Fungal Infection", "Fungemia", "Invasive Candidiasis", "Pneumocystis", "Mold Infection", "Invasive Fungal Disease", "Prophylaxis of Invasive Fungal Infections", "Aspergillus" ], "interventions": [ { "name": "Rezafungin for Injection", "type": "DRUG" }, { "name": "Posaconazole", "type": "DRUG" }, { "name": "Fluconazole", "type": "DRUG" }, { "name": "Trimethoprim-sulfamethoxazole (TMP/SMX)", "type": "DRUG" }, { "name": "Intravenous Placebo", "type": "DRUG" }, { "name": "Oral Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Mundipharma Research Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 602, "start_date": "2020-05-11", "completion_date": "2026-01-29", "has_results": false, "last_update_posted_date": "2026-04-13", "last_synced_at": "2026-09-27T06:24:52.002Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Los Angeles, California • Stanford, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04368559" }, { "nct_id": "NCT03013998", "title": "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Previously Untreated Relapsed Refractory Acute Myeloid Leukemia" ], "interventions": [ { "name": "Samalizumab (BAML-16-001-S1)", "type": "BIOLOGICAL" }, { "name": "BI 836858 (BAML-16-001-S2)", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Daunorubicin (BAML-16-001-S1)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S1)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S2)", "type": "DRUG" }, { "name": "AG-221 (BAML-16-001-S3)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S3)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S4)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S4)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S5)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S5)", "type": "DRUG" }, { "name": "Entospletinib (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Daunorubicin (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S6)", "type": "DRUG" }, { "name": "Pevonedistat (BAML-16-001-S9)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S9)", "type": "DRUG" }, { "name": "AG-120 (BAML-16-001-S16)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S16)", "type": "DRUG" }, { "name": "Gilteritinib (BAML-16-001-S8 Group 1)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S8 Group 1)", "type": "DRUG" }, { "name": "AZD5153 (BAML-16-001-S10)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S10)", "type": "DRUG" }, { "name": "TP-0903 (BAML-16-001-S14)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S14)", "type": "DRUG" }, { "name": "Decitabine (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "AZD5991 (BAML-16-001-S18)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S18)", "type": "DRUG" }, { "name": "SNDX-5613 (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S17)", "type": "DRUG" }, { "name": "Gilteritinib (BAML-16-001-S8 Group 2)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S12 Arm A)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S12 Arm A)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S12 Arm B)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S12 Arm B)", "type": "DRUG" }, { "name": "ZE46-0134 (BAML-16-001-S21 Group 1)", "type": "DRUG" }, { "name": "ficlatuzumab (BAML-16-001-S24)", "type": "DRUG" }, { "name": "Azacitidine (BAML-16-001-S24)", "type": "DRUG" }, { "name": "Venetoclax (BAML-16-001-S24)", "type": "DRUG" }, { "name": "ZE46-0134 (BAML-16-001-S21 Group 2)", "type": "DRUG" }, { "name": "Bleximenib (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Cytarabine (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Daunorubicin or Idarubicin (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Placebo (BAML-16-001-S25/HO181)", "type": "DRUG" }, { "name": "Revumenib (BAML-16-001-S26/HO177)", "type": "DRUG" }, { "name": "Placebo (BAML-16-001-S26/HO177)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Beat AML, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 3000, "start_date": "2016-11", "completion_date": "2032-12", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-09-27T06:24:52.002Z", "location_count": 31, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Los Angeles, California + 26 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03013998" }, { "nct_id": "NCT04825275", "title": "Neuro-pharmacological Properties of Repurposed Posaconazole in Glioblastoma: A Phase 0 Clinical Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Glioblastoma", "Glioblastoma Multiforme", "Glioblastoma Multiforme of Brain", "Glioblastoma Multiforme, Adult" ], "interventions": [ { "name": "Posaconazole Pill", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2022-05-13", "completion_date": "2024-11-06", "has_results": true, "last_update_posted_date": "2026-01-23", "last_synced_at": "2026-09-27T06:24:52.002Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04825275" }, { "nct_id": "NCT00253305", "title": "Topical Gel Anti-Fungal Agent for Tinea Unguium", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Onychomycosis" ], "interventions": [ { "name": "Organogel of naftifine, 2%", "type": "DRUG" }, { "name": "Organogel of terbinafine, 2%", "type": "DRUG" }, { "name": "Organogel of naftifine, 6%", "type": "DRUG" }, { "name": "Organogel of terbinafine, 6%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "MediQuest Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 75, "start_date": "2005-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2007-05-30", "last_synced_at": "2026-09-27T06:24:52.002Z", "location_count": 5, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Miami Beach, Florida + 2 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Miami Beach", "state": "Florida" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT00253305" }, { "nct_id": "NCT03667690", "title": "Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Candidemia", "Mycoses", "Fungal Infection", "Invasive Candidiases" ], "interventions": [ { "name": "Rezafungin for Injection", "type": "DRUG" }, { "name": "Caspofungin", "type": "DRUG" }, { "name": "Fluconazole", "type": "DRUG" }, { "name": "intravenous placebo", "type": "DRUG" }, { "name": "oral placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 199, "start_date": "2018-10-07", "completion_date": "2021-10-07", "has_results": true, "last_update_posted_date": "2023-01-06", "last_synced_at": "2026-09-27T06:24:52.002Z", "location_count": 19, "location_summary": "Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03667690" }, { "nct_id": "NCT04869449", "title": "Neuro-pharmacological Properties of Repurposed Ketoconazole in Glioblastomas", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Glioblastoma", "Glioblastoma Multiforme", "Glioblastoma Multiforme of Brain", "Glioblastoma Multiforme, Adult" ], "interventions": [ { "name": "Ketoconazole", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Milton S. Hershey Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2022-05-11", "completion_date": "2022-05-12", "has_results": false, "last_update_posted_date": "2026-01-07", "last_synced_at": "2026-09-27T06:24:52.002Z", "location_count": 1, "location_summary": "Hershey, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT04869449" }, { "nct_id": "NCT03136926", "title": "Screening Anti-Fungal Exposure in Intensive Care Units", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Antifungal Agents" ], "interventions": [], "intervention_types": [], "sponsor": "The University of Queensland", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 150, "start_date": "2017-01", "completion_date": "2018-12", "has_results": false, "last_update_posted_date": "2018-06-21", "last_synced_at": "2026-09-27T06:24:52.002Z", "location_count": 1, "location_summary": "New Orleans, Louisiana", "locations": [ { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03136926" }, { "nct_id": "NCT07215273", "title": "Phase 2 EL219 Versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Invasive Mould Infection" ], "interventions": [ { "name": "EL219", "type": "DRUG" }, { "name": "Active Comparator- IV Antifungal (LAmB or voriconazole)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Elion Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2026-02-13", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-09-25", "last_synced_at": "2026-09-27T06:24:52.002Z", "location_count": 10, "location_summary": "Birmingham, Alabama • Sacramento, California • Augusta, Georgia + 7 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sacramento", "state": "California" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07215273" }, { "nct_id": "NCT06146504", "title": "Clinical Study to Evaluate the Efficacy of an Anti-Fungal Supplement", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Candida Systemic", "Candida Albicans Infection", "Candida Infection" ], "interventions": [ { "name": "CanXida Remove (Formula RMV)", "type": "DIETARY_SUPPLEMENT" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DIETARY_SUPPLEMENT", "OTHER" ], "sponsor": "CanXida", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 60, "start_date": "2023-11-30", "completion_date": "2024-06-28", "has_results": false, "last_update_posted_date": "2024-08-22", "last_synced_at": "2026-09-27T06:24:52.002Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06146504" } ] }